ENT

Your Article Summary

See Latest Articles

Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer
Journal of Cancer Research & Clinical Oncology, 06/30/09

Chen MH et al. - In a study to test whether the pretreatment hematologic profile can predict prognosis of pts with head and neck cancer (HNC), it was shown that a pretreatment hematologic profile can be considered as a useful prognostic marker in pts with HNC.

• Medical records from 278 pts with HNC were reviewed, and 270 cases were evaluable.
• Clinical data including age, gender, stage, pretreatment hematologic profile (including white blood cell, platelet, and differential counts, and hemoglobin level) were recorded.
• Statistical analyses were performed to determine the prognostic effect of these hematologic indicators, as well as clinical variables.
• Association between hematologic indicators and clinical factors was also analyzed.

• Pretreatment monocytes >1000 cells/μl, hemoglobin <11.0 g/dl, and platelet count >400 x 103 cells/μl were identified as independent prognostic factors in addition to nodal status and metastasis.
• A significant correlation between T-stage/monocyte or platelet count and metastasis/platelet count were shown.
• Monocytosis, anemia, and thrombocytosis were demonstrated to have a cumulative effect on prognosis of HNC pts (normal vs abnormality in 1 lineage; abnormality in 1 vs >1 lineage).

Today in Head and Neck...keeping you current

Receive free subspecialty "5-minute updates" via email

Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer
Thyroid, 11/02/09

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09

Diagnostic Pediatric Computed Tomographic Scans of the Head: Actual Dosage versus Estimated Risk
Plastic and Reconstructive Surgery, 10/12/09

See All of Head and Neck